| Literature DB >> 23352656 |
Frédérique Penault-Llorca1, Renata A Coudry2, Wedad M Hanna3, Robert Y Osamura4, Josef Rüschoff5, Giuseppe Viale6.
Abstract
The human epidermal growth factor receptor 2 (HER2) and hormone receptor status of recurrent breast cancer may change between the tumor and metastases from negative to positive and vice versa, potentially affecting the treatment regimen. Retesting of metastases may therefore be crucial to allow appropriate selection of patients for whom targeted therapy is indicated; however, retesting is not routinely performed. This article recommends that metastases be retested for HER2 and hormone receptor status and provides practical guidance on when and how to retest, as agreed by a panel of expert pathologists with extensive experience of HER2 and hormone receptor testing.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23352656 DOI： 10.1016/j.breast.2012.12.004
Source DB: PubMed Journal: Breast ISSN： 0960-9776 Impact factor: 4.380